Skip Nav Destination
Issues
1 April 2019
-
Cover Image
Cover Image
ABOUT THE COVER
Recent reports indicate a high correlation between fast food intake and lung cancer incidence. Benzo[a]pyrene (B[a]P) is a potent carcinogen abundantly present in grilled and deep-fried food and in tobacco smoke. Efficacy of curcumin, a known dietary chemopreventive agent, in B[a]P-induced lung carcinogenesis is well established. However, the poor pharmacokinetic profile of the compound hampers its potential for clinical use. A study by Anto and colleagues (beginning on page 225) demonstrates that encapsulation of curcumin in chitosan nanoparticles improves cell uptake and prolongs tissue retention of curcumin, thereby increasing the compound's chemopreventive activity. Bioavailability studies using healthy Swiss albino mice showed drastic enhancement in lung localization of chitosan nanocurcumin compared to free curcumin. Toxicologic evaluation confirmed the pharmacologic safety of the formulation, which, even at a dose equivalent to one-fourth that of free curcumin, exhibited higher efficacy in reducing tumor incidence and multiplicity than free curcumin. These results underscore the supremacy of chitosan–curcumin formulation over free curcumin and establish its potential as an oral supplement to prevent B[a]P- and other environmental carcinogen-induced cancers. The cover image depicts intracellular uptake of chitosan nanocurcumin (equivalent to 25 μM curcumin) in H1299 lung cancer cells. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Research Articles
Chitosan Encapsulation Enhances the Bioavailability and Tissue Retention of Curcumin and Improves its Efficacy in Preventing B[a]P-induced Lung Carcinogenesis
Vinod Vijayakurup; Arunkumar T. Thulasidasan; Mohan Shankar G; Archana P. Retnakumari; C. Devika Nandan; Jannet Somaraj; Jayesh Antony; Vijai V. Alex; Balachandran S. Vinod; Vijayasteltar Belsamma Liju; Sankar Sundaram; G. S. Vinod Kumar; Ruby John Anto
A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women
Li Jiao; Suman Maity; Cristian Coarfa; Kimal Rajapakshe; Liang Chen; Feng Jin; Vasanta Putluri; Lesley F. Tinker; Qianxing Mo; Fengju Chen; Subrata Sen; Haleh Sangi-Hyghpeykar; Hashem B. El-Serag; Nagireddy Putluri
JAK3 Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients
Rafael Guerrero-Preston; Fahcina Lawson; Sebastian Rodriguez-Torres; Maartje G. Noordhuis; Francesca Pirini; Laura Manuel; Blanca L. Valle; Tal Hadar; Bianca Rivera; Oluwasina Folawiyo; Adriana Baez; Luigi Marchionni; Wayne M. Koch; William H. Westra; Young J. Kim; James R. Eshleman; David Sidransky
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.